Micafungin + Liposomal Amphotericin B

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis

Conditions

Candidiasis

Trial Timeline

Jan 1, 2003 → Dec 1, 2005

About Micafungin + Liposomal Amphotericin B

Micafungin + Liposomal Amphotericin B is a phase 3 stage product being developed by Astellas Pharma for Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00106288. Target conditions include Candidiasis.

What happened to similar drugs?

5 of 20 similar drugs in Candidiasis were approved

Approved (5) Terminated (4) Active (12)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00106288Phase 3Completed
NCT00047827Phase 2Terminated

Competing Products

20 competing products in Candidiasis

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
29
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Fluconazole + MicafunginAstellas PharmaApproved
35
Micafungin + CaspofunginAstellas PharmaPhase 3
40
Micafungin + FluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPhase 2
35
micafungin + caspofunginAstellas PharmaPhase 3
40
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
32
FK463Astellas PharmaPhase 2
35
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
36
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
36
L-743,872MerckPre-clinical
26
CaspofunginMerckPhase 2
35
L-743,872MerckPhase 2
27
Caspofungin + Amphotericin B DeoxycholateMerckPhase 2
27
Caspofungin acetate + PlaceboMerckPhase 2
27
Caspofungin + Normal SalineMerckApproved
43
caspofungin acetateMerckPhase 3
40